Restricted mean survival time as outcome measure in advanced urothelial bladder cancer: analysis of 4 clinical studies-Reference-Cited by-同舟云学术

Restricted mean survival time as outcome measure in advanced urothelial bladder cancer: analysis of 4 clinical studies

Published:2021-02 Issue:2 Volume:13 Page:95-101
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Rivano Melania¹^ORCID,Cancanelli Luca²^ORCID,Spazio Lorenzo Di³^ORCID,Chiumente Marco⁴^ORCID,Mengato Daniele⁵^ORCID,Messori Andrea⁶^ORCID

Affiliation:

1. Clinical Oncology Pharmacy Department, A. Businco Hospital, 09121 Cagliari, Italy

2. Hospital Pharmacy Department, Azienda ULSS 2 Marca Trevigiana, 31033 Castelfranco Veneto, Italy

3. Hospital Pharmacy Department, S.Chiara Hospital, 38122 Trento, Italy

4. Scientific Direction, Italian Society for Clinical Pharmacy & Therapeutics, Milan, Italy

5. Hospital Pharmacy Department, Bolzano General Hospital, 39100 Bolzano, Italy

6. HTA Unit, Regional Health Service, Florence, Italy

Abstract

Background: The purpose of this study was to assess the effectiveness of immune checkpoint inhibitors (ICIs) in advanced urothelial carcinoma. Materials & methods: We selected seven cohorts of patients published in four clinical trials. The restricted mean survival time (RMST) was used to analyze survival curves, perform the comparisons and rank the treatments based on their effectiveness. The performance of RMST was compared with that of a network meta-analysis. Results: Three ICIs, vinflunine and best standard care, given as second line, were examined. ICIs significantly improved overall survival compared with best standard care. However, the survival gain was quite limited (up to 2.27 months). Post hoc pairwise comparisons were calculated. Conclusion: Our results summarized the efficacy of these treatments and confirmed the good methodological performance of RMST.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2020-0160

Reference31 articles.

1. Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987

2. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

3. Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

4. Cisplatin-Ineligible and Chemotherapy-Ineligible Patients Should Be the Focus of New Drug Development in Patients With Advanced Bladder Cancer

5. Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Restricted Mean Survival Time—Can It Be a New Tool in Assessing the Survival of Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors?;Diagnostics;2023-05-29

2. Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses;Cancers;2023-03-07

3. The “One-to-Many” Survival Analysis to Evaluate a New Treatment in Comparison With Therapeutic Alternatives Based on Reconstructed Patient Data: Enfortumab Vedotin Versus Standard of Care in Advanced or Metastatic Urothelial Carcinoma;Cureus;2022-08-25

4. Combining TMEM Doorway Score and MenaCalc Score Improves the Prediction of Distant Recurrence Risk in HR+/HER2− Breast Cancer Patients;Cancers;2022-04-26